Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

10 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Findings add surprising new dimension to understanding of antibody repertoires

As elite soldiers of the body's immune response, B cells serve as a vast standing army ready to recognize and destroy invading antigens, including infections and cancer cells. To do so, each new B cell comes equipped with its own highly specialized weapon, a unique antibody protein that selectively binds to specific parts of the antigen.

10 Jun 2014

Wistar findings suggest means of boosting initial immune response

Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective.

10 Jun 2014

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Researchers move closer to establishing link between GAD65 protein and type 1 diabetes

Researchers are a step closer to establishing the link between a protein with a split personality and type 1 diabetes.

10 Jun 2014

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells-specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

10 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

The Epstein-Barr virus (EBV) is a member of the herpes family that targets lymphocytes and epithelial cells. While the infection is usually benign, it can in some cases lead to acute infectious mononucleosis and can impair the immune system. EBV is also linked to several malignancies. There is currently no cure for removing EBV infections and very little success treating acute EBV infection and mononucleosis with drugs.

4 Jun 2014

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

4 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.

4 Jun 2014

Researchers develop antibodies that reduce liver damage, recovers liver function

A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

4 Jun 2014

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

4 Jun 2014

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities.

3 Jun 2014

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

2 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

Antibody News and Research

Further Reading

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Findings add surprising new dimension to understanding of antibody repertoires

Wistar findings suggest means of boosting initial immune response

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

Researchers move closer to establishing link between GAD65 protein and type 1 diabetes

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

Researchers develop antibodies that reduce liver damage, recovers liver function

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo